LOS ANGELES, Aug. 2, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, indicates an ongoing investigation concerning investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) ZNTL for potential securities law infringements.
The inquiry centers on whether the Company disseminated deceptive information or omitted crucial details relevant to investors. Zentalis disclosed on June 18, 2024, that the “U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”
Shareholders who have suffered losses are encouraged to participate by contacting the Schall Law Firm. The firm specializing in securities class action lawsuits and shareholder rights litigation vows to represent investors globally.
This press release serves as Attorney Advertising in specific jurisdictions under applicable regulations. Investors with concerns can engage with the Schall Law Firm to explore their legal rights free of charge and potentially seek redress.
View original content to download multimedia: Full article here
SOURCE The Schall Law Firm